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α-lipoic acid (ALA) functions as a cofactor in the multi-en-
zyme complexes that catalyze the oxidative decarboxylation 
of a-keto acids such as pyruvate, c-ketoglutarate, and bran-
ched chain a-ketoacids. ALA, converted to dihydrolipoic acid 
(DHLA) in many tissues, was tentatively classified as a vita-
min. ALA also has the components of the redox couple that 
effectively quenches a number of free radicals in both lipid 
and aqueous domains. It also acts synergistically with other 
antioxidants. So it has the specific advantages to aid in the 
recovery from an ischemia-reperfusion injury. After it is pro-
ven that ALA inhibition of platelet aggregation is mediated 
by PPARα/γ-dependent processes, which involve interaction 
with PKCα and COX-1, increase of cyclic AMP formation, 
and inhibition of intracellular Ca(2+), ALA has gained more 
attention.
1)
The author suggested in a previous study that ALA feeding 
and ALA-coated stents inhibit neointimal hyperplasia in 
porcine ISR, possibly through inhibiting the activation of the 
NF-κb pathway and proliferation of PVSMC. So it is a prom-
ising agent for protecting neoatherosclerosis after drug-elut-
ing stent (DES) stenting.
2)
But several recently-published studies failed to demonst-
rate that ALA-coated stents actually reduced neointimal hy-
perplasia. It will be a problematic issue to deal with DES re-
stenosis and obtain new optimal target macromolecules. 
Nevertheless, it was suggested that ALA increased p38 mito-
gen-activated protein kinase phosphorylation, and inhibi-
tion of p38 mitogen-activated protein kinase completely bl-
ocked ALA-induced vascular smooth muscle cell apoptosis, 
Nur77 induction, and cytoplasmic localization. In balloon-
injured rat carotid arteries, ALA enhanced Nur77 express-
ion and increased TUNEL-positive apoptotic cells in the neo-
intima, leading to inhibition of neointimal hyperplasia.
3)
Existing antioxidative agents have various drawbacks, in-
cluding instability in water, lack of efficacy in clinical I/R 
conditions, and/or toxicity to healthy cells. DHL-HisZn is a 
new synthetic a-lipoic acid derivative that contains ALA, his-
tidine, and zinc. It is soluble and stable in aqueous solutions. 
DHL-HisZn has anti-oxidative properties and exerts a strong 
protective effect against renal I/R injury. Thus, it is believed 
that DHL-HisZn has potential as an antioxidant for thera-
peutic applications.
4)
Authors previously reported that an abciximab-coated 
stent was effective in the prevention of in-stent neointimal hy-
perplasia, and there was no acute or subacute stent throm-
bosis even in patients with acute myocardial infarctions and 
unstable angina. Possible explanation was that abciximab 
blocked platelet aggregation and reacts to CD11b/CD18 of 
vascular endothelial cells and macrophages, and inhibits in-
flammatory reactions and proliferation of vascular smooth 
muscle cells.
5)6)
To obtain platforms able to surmount some issues associ-
ated with available devices and widen their fields of applica-
tion, the current generation of DES has continuously evolv-
ed. By varying a polymer matrix, current stents have a tun-
able release rate in the first month of delivery. DES covered 
with anti-proliferative or anti-inflammatory drugs have ac-
tually made a significant difference in lowering restenosis 
rates from 30% to 5%. Nowadays, most agents loaded onto st-
ents such as sirolimus, paclitaxel, or everolimus are relatively 
well established in terms of release kinetics with respect to 
the particular delivery system. However, in the development 
of new DESs, the main responsibility of delivery rates is a 
covered drug dissolution rate when eluted in a polymeric ma-
Evolving Coronary Stents Coated With New Bioactive Agents
Yunseok Choi, MD
Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea234   Evolving Coronary Stents
trix. The delivery rate of therapeutics is thus a quite variable 
but very important field. So, studies about emerging appro-
aches to improve potential therapeutic DES applications to 
the incorporation of bio-compatible anti-proliferative and an-
ti-inflammatory agents other than widely-used low-molecu-
lar-weight lipophilic compounds were performed. Those ag-
ents are able to attain the desired anti-proliferative, biocom-
patible effect. Among all the candidates of molecules 
nowadays under consideration, anti-oxidatives and anti-in-
flammatories could play a crucial role. However, development 
of new combinations of therapeutic agents is required, imply-
ing that their use has been limited to few studies due to diffi-
culties in having an efficacious duration and human trials. 
For the production of completely innovative DES, DES sh-
ould be engineered to provide a fine tuning of delivery rate 
which is critical to drive full benefit and lesser traumatic on 
tissue compatibility. A full tuning of drug loading and release 
kinetics are much more challenging, not only characterized 
by unique pharmacological properties but also by specific 
delivery requirements in order to be successful. Therefore, the 
introduction of new delivery systems and favorable bioactive 
agents into the basic platform of the stent must be now tak-
ing place in clinical practices.
In all the current DES, the release of the drugs dispersed 
within the polymeric matrices is uniformly controlled by a 
diffusion mechanism. Especially for devices working in di-
rect contact with biological fluids, such as blood in the case 
of the stent, the release kinetics of hydrophilic agents homo-
geneously dispersed in polymeric coating are expected to be 
too fast for achieving a prolonged therapeutic effect.
7)
In this study,
8) drug coatings in stents are done stepwise to 
get a strong binding between drug and stent polymer. How-
ever, all these activities to overcome the current DES limita-
tion such as stent thrombosis and delayed endothelialization 
are still investigated more extensively in terms of the release 
of small lipophilic molecules. These works are at the initial 
stage of characterization, which can determine the further re-
duction of therapeutic windows from months to a few days 
or even hours. One of the big problems of DES-implanted pa-
tients was a complication of late stent thrombosis, which 
was completely associated with stent polymers. One of the 
postulated mechanisms of late stent thrombosis was hyper-
sensitivity for polymers and inflammatory reactions. In this 
study, a dual-coating stent could prevent lymphohistiocyte 
infiltration despite failing to reduce the neointima area in a 
dual-coated stent compared with BMS. That means that it 
causes a lesser degree of inflammatory reactions in a dual-
coating stent. As shown in Fig. 1,
8) dual-coated agents were 
almost completely released within two weeks. So the benefi-
cial effects of early pharmacokinetics need to be elucidated 
further.
It is true that a lot of data and research to overcome the li-
mitations of current DES stents has been introduced. Many 
investigators are scrambling to find the best solution. There-
fore, we do ardently hope for the new therapeutic options 
and path-breaking technology about evolving the current 
state of DES.
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